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Purpose: The purpose of this study was to evaluate the cost-effectiveness of creening for 
abdominal aortic aneurysms (AAA) during noninvasive lower extremity arterial exami- 
nation in the vascular laboratory. 
Methods: Over 30 months we screened 531 patients who underwent lower extremity 
arterial evaluations in the vascular laboratory. The patients had fasted overnight, and, after 
the regular noninvasive lower extremity arterial examination, the abdominal aorta was 
screened with B-mode ultrasonography. 
Results: The aorta was adequately visualized in 475 patients (89%). Mean aortic diameter 
was 19.6 + 4.1 mm at the juxtarenal level and 18.8 + 7.2 mm in the lower infrarenal 
aorta. The aortic diameter was larger in men (p < 0.001) and in smokers (p < 0.001). 
AAA (diameter greater than 3.0 cm) were identified in 32 patients (6.0% of the 531 
patients creened), and 15 of the aneurysms were equal to or larger than 4.0 cm. The best 
predictors for AAA by logistic regression analysis were male sex (p < 0.005), advanced age 
(greater than 65 years,p < 0.01), and a history of smoking (p < 0.01). The prevalence of 
AAA was 6.7% (32/475) in the population in whom the aorta was visualized and 15.2% 
(19/125) in male smokers over 65 years of age. Aneurysms of 4.0 cm or greater were 
identified in 3.2% of the entire population screened and 8.8% of male smokers over age 
65. Limited aortic scanning prolonged the vascular laboratory examination by an average 
of 5 minutes. Thus detection of one aneurysm required 83 minutes of scanning time for 
the whole population studied and 36 minutes of scanning of male smokers over age 65, 
at a cost of $240 to $553 per aneurysm identified. 
Conclusion: Screening for AAA during lower extremity arterial evaluation in the vascular 
laboratory addresses a high-risk population, iscost-effective, and should be considered an 
appropriate and valuable addition to the examination protocol. (J VAsc SURG 1995; 
22:417-23.) 
The mortality rate associated with rupture of 
abdominal aortic aneurysms (AAA) remains high 
(64% to 94%), and about half of  the deaths occur 
before arrival at the hospital.t,2 The key to lowering 
this mortality rate is early identification of these 
aneurysms and their elective repair. The prevalence of  
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AAA in one study of the general population was 
4.3% in men aged 65 to 74. 3 It was 4.2% in another 
study and 7.4% in men over age 74. 4's Patients with 
peripheral arterial occlusive disease also are known to 
have a high prevalence of AAA. 6-9 Thus we postulated 
that a visit to the vascular laboratory would present 
an excellent opportunity to screen for the presence of  
AAA and to evaluate the cost-effectiveness of this 
approach. 
PAT IENTS AND METHODS 
From lanuary 8, 1990, to January 2, 1993, 
approximately 2400 patients were evaluated for 
lower extremity arterial disease in our vascular 
laboratory. All of  the patients who were referred to 
the laboratory by the Vascular Surgery service were 
asked to fast overnight when scheduled for the 
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Table I. Demographics of the screened populations 
Total population Patients with AAA 
screened (n = 531) (n = 32) Significance 
Age (yr) 68.8 + 9.2 72.2 + 7.8 p < 0.05 
Men 58% (309/531) 88% (28/32) p < 0.005 
Smokers 66% (340/513) 90% (27/30) p < 0.005 
CAD 36% (183/505) 40% (12/30) NS 
Hypertension 51% (263/516) 43% (13/30) NS 
Diabetes 16% (83/512) 17% (5/30) NS 
ABPI* 0.85 -+ 0.26 0.72 _+ 0.24 p < 0.005 
*Lowest resting ABPI. 
Table II. Aortic diameter as measured by 
ultrasonography in the lower infrarenal aorta 
Aortic diameter 
(ram) All cases Women Men 
i0-19 329 163 166 
20-29 114 28 86 
30-39 17 3 14 
40-49 9 1 8 
50-59 4 0 4 
~60 2 0 2 
examination; 531 patients arrived for the examina- 
tion after an overnight fast and are included in this 
report. During their visit, a history of smoking and 
the presence of coronary artery disease (CAD), 
hypertension and diabetes were recorded. The smok- 
ing history was considered positive if it was greater 
than 10 pack-years, and CAD was considered present 
if the history was positive for angina pectoris, 
myocardial infarction, or coronary artery bypass. 
Hypertension (systolic > 140 mm Hg) and diabetes 
were recorded as present if previously diagnosed and 
treated medically. 
After the routine lower extremity arterial exami- 
nation, the abdominal aorta was scanned with 
B-mode ultrasonography with an Ultramark 4 scan- 
ner (Advanced Technology Laboratories, Seattle, 
Wash.) with a 3 or 5 MHz  mechanical transducer. 
The same device also was used routinely in the lower 
extremity arterial examinations in this laboratory. 
The patient was studied in the supine position, and 
the aorta was scanned transversely through the ante- 
rior abdominal wall. Anteroposterior and lateral di- 
mensions of the aorta at the juxtarenal level and in the 
distal infrarenal portion were recorded. An AAA was 
defined as an infrarenal aorta measuring more than 
3.0 cm in anteroposterior  transverse diameter. ~° 
Statistical analyses included t testing and chi- 
square analyses, where appropriate. Stepwise logistic 
regression analysis was used for the identification of 
predictors for the presence ofAAA. Ap < 0.05 was 
considered significant. 
RESULTS 
Five hundred thirty-one patients were screened 
for AAA in the vascular laboratory during the 
30-month study period. Their mean age was 
68.8 _+ 9.2 years, and 222 (42%) were women 
(Table I). Screening for AAA used the same equip- 
ment as was used for peripheral arterial screening and 
added approximately 5 minutes to the standard lower 
extremity peripheral arterial examination in the 
laboratory (range 2 to 7 minutes). Aside from the 
overnight fast, the abdominal examination was not 
associated with any discomfort. The aorta was 
adequately visualized in 475 (89%) patients. The 
mean aortic diameter was 18.8 _+ 7.2 mm in the 
inferior portion of the infrarenal aorta and 
19.6 -+ 4.1 mm at the juxtarenal evel (Table II). 
These dimensions did not differ significantly for 
anteroposterior and transverse measurements. The 
aortic diameter was larger in men at 20.7 _+ 8.2 mm 
than in women, who averaged 16.2 _+ 4.2 mm 
(p < 0.001), andlarger in smokers (p < 0.001)and 
was inversely related to the lowest resting anlde- 
brachial pressure index (ABPI) (p < 0.01; r = 
- 0.14). It was not significantly related to age or to 
the presence of CAD, hypertension, or diabetes. 
Thirty-two patients with AAA of 3.0 cm or 
greater were identified (Table I). None of the 
aneurysms extended above the renal arteries, and 15 
were 4.0 cm or greater in maximum transverse 
diameter (Table II). The best predictors for the 
presence of AAA by logistic regression analysis were 
male sex (p < 0.005), advanced age (p < 0.01), 
and a positive history of smoking (p < 0.01). The 
presence of AAA was not significantly associated 
with CAD, hypertension, diabetes, or lowest resting 
ABPI. However, the mean value of ABPI was 
significantly lower in patients with aneurysms. The 
prevalence of AAA of 3.0 cm or greater was 6.7% 
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Table III, A. Prevalence of AAA of 3.0 cm or greater in screened population and subgroups 
Prevalence of AAA % of AAA Scanning time/AAA 
>3.0 cm >3.0 mm identified >3.0 cm (rain.) 
Whole population 6.7% (32/475) 100% 83 
Men 10.0% (28/280) 88% 55 
Male smokers 11.9% (23/194) 72% 46 
Male smokers > 65 yr. 15.2% (19/125) 59% 36 
Table III, B. Prevalence of AAA of 4.0 cm or greater in screened population and subgroups 
Prevalence of AAA % of AAA Scanning time/AAA 
>4.0 cm >4.0 mm identified >4.0 cm (rain.) 
Whole population 3.2% (15/475) 100% 177 
Men 5.0% (14/280) 93% 110 
Male smokers 6.2% (12/194) 80% 89 
Male smokers >65 yr. 8.8% (11/125) 73% 62 
Table IV. Screening for AAA by ultrasonography 
Prevalence * 
Author (refi) Year Country No. Population screening > 3 cm/4 cm 
Cabellon 6 1983 USA 73 PVD or CAD 9.5%t 
Twomey i6 1984 UK 84 Men > 50 yr., HTN 10.7%~- 
Lindholm 23 1985 Sweden 245 50-69 yr., HTN 0.4%t 
Thurmond i7 1986 USA 120 > 50 yr., cardiology clinic patients 23.0%/5.0% 
Allen 24 1987 UK 168 > 65 yr. 1.7%/0.6% 
Allardice 7 1988 UK 100 PVD 10.0%/5.0% 
Lederle 18 1988 USA 201 Men 60-75 yr., HTN or CAD 9.0%/5.0% 
Collin 4 1988 UK 745 Men 65-74 yr. 4.2%/2.0% 
O'Kelly 25 1989 UK 906 Men 65-74 yr. 5.0%/1.5%~ 
Berridge 8 i989 UK 104 PVD 6.7%/5.7% 
Shapira 9 1990 Israel 101 PVD 4.0%/2.0% 
Bengtsson s 1991 Sweden 375 Men 74 yr. 7.6%/3.3% 
Scott 3 1991 UK 4,237 65-80 yr. 4.3%/1.3% 
Carty 26 1993 USA 131 Carotid artery duplex 8.4%/2.3% 
USA, United States of America; PVD, peripheral vascular disease; UK, United Kingdom; HTN, hypertension. 
*The prevalence rate was calculated as the fraction of those visualized and was corrected for the definition of size, where 
~Size of AAA not specified. 
~cNumbers reported for aortic diameter greater than 2.5 cm (7.8%) and greater than 4.0 cm (1.5%). 
possible. 
in the whole population in whom the aorta was 
visualized, 10.0% (28/280) in men, and 11.9% 
(23/194) in male smokers. The highest prevalence 
of 15.2% (19/125) occurred in male smokers over 
the age of 65 who constituted 26.3% (125/475) of 
the population and in whom 59.3% (19/32) of the 
aneurysms were found (Table III). Aneurysms of 
4.0 cm or greater were identified in 3.2% (15/475) 
of the entire population screened, and in 8.8% of 
the male smokers over age 65, in whom 73% of 
aneurysms of 4.0 cm or greater were diagnosed 
(Table III). 
DISCUSSION 
In this study we screened the aorta in patients 
who underwent lower extremity arterial evaluation in 
the vascular laboratory. The dimensions of the aorta 
were 19.6 -+ 4.1 mm at the juxtarenal level and 
18.8 _ 7.2 mm in the lower portion of the infrarenal 
aorta, and the diameter was larger in men and in 
smokers. These values are comparable to other 
studies. 11,12 In one report, the infrarenal aorta mea- 
sured 23 -+ 1 mm in healthy men and 19 _+ 1 mm in 
healthy women by computed tomography scan- 
ning. n In another study, the distal infrarenal aorta 
was examined by ultrasonography and measured 
17 _+ 2 mm in men and 15 + 2 mm in women 
without vascular disease. 12 Aortic size is known to 
increase with advancing age H but did not correlate 
with age in this study. This may be due to the patient 
selection criteria of known or suspected peripheral 
arterial disease (76% of the patients screened in this 
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study were between 60 and 80 years old). The aortic 
diameter was weakly and inversely related to the 
lowest ABPI. This association may reflect he pres- 
ence of common risk factors for atherosclerosis and 
aortic dilation. 
The prevalence of previously unknown abdomi- 
nal aneurysms was 6.7% of those patients in whom 
the aorta was visualized in this population. Other 
series of patients "with peripheral vascular disease have 
reported aprevalence of abdominal aneurysms rang- 
ing from 4% to  10%.  6.9 The presence of AAA was 
associated with male sex, advanced age, and smoking, 
all previously shown to be associated with AAA. ls~s 
Contrary to other studies, however, CAD and 
hypertension were not associated with an increase in 
the prevalence of AAA in this study 16-1s (Table IV). 
When added to routine lower extremity arterial 
examination i the vascular laboratory, the additional 
effort for limited aortic scanning was minimal and on 
average prolonged the examination by 5 minutes 
(measured time in the last 50 patients ranged from 2 
to 7 minutes). Thus, for the entire population 
screened, identification of one aneurysm of 3.0 cm or 
greater required 83 minutes of aortic scanning. 
Selecting only men for screening would identify 88% 
of aneurysms at 50 minutes of screening per aneu- 
rysm detected and selecting male smokers over age 65 
would identify 60% of aneurysms at 36 minutes of 
screening per aneurysm identified (Table III). 
A full peripheral arterial examination in our 
vascular laboratory takes 90 minutes and is billed at 
$815, including both technical and professional 
components. At that rate, the time spent for abdomi- 
nal aortic screening would cost $45.28. Thus the cost 
of identifying asingle aneurysm of 3.0 cm or greater 
would range from $326 to $752, and the cost of 
identifying an aneurysm of 4.0 cm or greater would 
range from $561 to $1603, depending on the 
selection of the population to be screened (Table III). 
These cost estimates are significantly less than previ- 
ous estimates of the costs of screening when separate 
ultrasound examinations are used. 19 Estimates of the 
costs of such separate ultrasonic screening procedures 
have been reported as $100 to $150 in the litera- 
ture.2°,21 However, in our institution, the current cost 
for a separate abdominal aortic ultrasound study is 
$334, including both the technical and professional 
components, compared with the $45.27 cost in our 
vascular laboratory. Thus the vascular laboratory is 
not only a source of preselected patients more likely 
to have previously undetected aneurysms, but also a 
less expensive site in which to make this diagnosis. 
Vascular laboratory costs were 33% to 50% of the 
total costs of a screening program in the reports of 
Quill et al.21 and Frame, 2° with the majority of the 
expense associated with the elective repair of those 
aneurysms detected. The projected cost of $413 to 
$1180 for tl~e identification of a single aneurysm of 
4.0 cm or greater is very low for the identification of 
a potentially fatal, but correctable, condition. These 
figures for aneurysm detection compare favorably 
with the average cost of identifying a breast cancer, 
estimated at $23,000, and the benefits of screening 
for the two conditions measured as quality life- 
years. 22 
The cost of screening isa minor component of the 
total expense related to a full screening project for 
AAA, because more than 80% of the overall expen- 
diture would relate to the elective surgical repair of 
the identified aneurysms. 19'2° The estimated overall 
cost of one life saved by detection through screening 
for AAA with elective surgical repair has been 
estimated at $88,000 to $119,000,1921 but the actual 
cost will have to be ascertained in large screening 
studies that include treatment outcome. Only then 
will we be able to decide on the desirability of 
large-scale, general population-based screening 
projects for AAA, including such issues of patient 
selection as age, sex, and frequency of repeat ultra- 
sound examination, if the result is initially negative. 
From the standpoint of the individual patient and 
physician, the issue is simpler. In this case, making 
use of a convenient and inexpensive opportunity to 
identify AAA in the vascular laboratory clearly seems 
worthwhile. 
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D ISCUSSION 
Dr. Wil l iam C. Krupski (Denver, Colo.). Dr. Wolf 
and colleagues have contributed meticulous investigation 
that adds substantially to our knowledge of AAA-a  
subject hat Dr. Bernstein first addressed decades ago. 
The incidence of AAA seems to be increasing. Two 
separate studies from the Mayo Clinic that examined the 
period 1951 to 1980 showed a threefold increase in 
prevalence from 12.2 per 100,000 to 36.2 per 100,000. 
Some of this increase in frequency may be related to 
improved etection owing to technologic advances, but the 
magnitude of the difference suggests a genuine increase. 
The aging of the population also plays a role in the 
increasing incidence. This was emphasized in a European 
autopsy study in which aneurysms occurred with a steadily 
increasing frequency in men after age 55, peaking at 5.9% 
in 90-year-old men. Women had development of an 
increased incidence of aneurysms after age 70, peaking at 
4.5% in 90-year-old women. Mortality data also reflect a 
real increase in the prevalence of AAA. Since 1951 the 
number of deaths caused by ruptured aneurysms in 
individuals under age 65 has remained low, but rates have 
risen in older age groups. It is intriguing that aneurysms are 
increasingly common whereas deaths from heart disease~ 
which shares the same risk factors, have decreased by 20% 
in the past decade. 
The economic ost of ruptured aneurysms i stagger- 
ing. A 1984 article written by Pasch and colleagues from 
Rochester, New York, estimated that $ 50 million and 2000 
lives could have been saved if aneurysms had been repaired 
before they ruptured. On the basis of such costs, it seems 
fiscally sound to screen individuals for AAAs and repair 
them on an elective basis. However, given the variable 
incidence ofaneurysms, determination f cost-effectiveness 
is complicated. In a thoughtful discussion of the cost- 
benefit of aneurysm screening, Quill and associates noted 
that in 1985, with an average cost of $150 for an abdominal 
ultrasound examination, it would cost about $4.3 billion to 
scan all persons at risk. This amounts to a cost of $360,000 
per life saved, provided that all patients found to have an 
AAA underwent operation and there were no operative 
deaths (an unlikely assumption). 
In addition to this report, a host of studies have been 
published concerning ultrasound screening for AAA. Three 
large-scale screening programs (combined with trials to 
investigate he prognosis and optimal management of small 
asymptomatic AAA) were introduced in this decade in the 
United Kingdom, Canada, and the United States. Al- 
though follow-up regimens and precise size criteria differ 
slightly, the three studies are remarkably similar in design. 
The Canadian Small Aneurysm Trial has been discontinued 
because of inadequate patient accrual. The United King- 
dom Small Aneurysm Trial is enrolling 1000 patients 60 to 
76 years old with AAAs of 4.0 to 5.4 cm. The United States 
small aneurysm study is designated by the acronym ADAM 
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(Aneurysm Detection and Management) and the details of 
the study design have recently been reported. As of 
December 1993, 38,697 patients had been screened with 
ultrasonography. 
This is one of several reports to confirm a high 
incidence of AAAs in patients with peripheral vascular 
disease. How severe was this disease? Did most patients 
have claudication or limb-threatening ischemia? What was 
the mean ABI in the series? The aorta could not be 
visualized in 11% of patients. Please describe the reasons 
for this. Did the incidence of nonvisualization improve 
over the course of the study? An average scanning time of 
5 minutes seems quite low. How experienced are your 
technologists and did scanning time decrease over the 
course of the study? It has been reported that 18% of 
patients with an AAA have a first-degree r lative with this 
disorder. Did you analyze this as a risk factor? Only 6 of 
531 patients-had aneurysms of 5 cm or greater. Many 
surgeons do not routinely operate on aneurysms of 5 cm or 
less. What is your policy regarding the best management of 
so-called "small" aneurysms? How many of the 15 patients 
with aneurysms of 4 cm or greater underwent operative 
repair? Finally, how do you reconcile your conclusion 
that AAA screening is cost-effective with the data from 
Quill et al.? 21 
Dr. Yehuda G. Wolf. Most of the patients creened 
had relatively mild peripheral arterial occlusive disease. 
Most had intermittent dandication, and the mean ABPI 
was 0.85. An aneurysm prevalence of 6.7% in our study is 
actually lower than the previously reported rate of about 
10% in patients with peripheral arterial occlusive disease in 
earlier, smaller studies. 
The incidence of nonvisualization f the aorta did not 
change along the course of the study, and it was related to 
the occasional presence of bowel gas, our insistence on 
visualization of the aorta at two levels, and measurement of 
the diameter at both levels. 
The technicians of the vascular laboratory are very 
experienced. The time necessary to scan the aorta did not 
change along the course of this study, and, because the 
patient was already positioned and the instrumentation was 
readily available, the 5-minute period reflects actual scan- 
ning time. 
We did not record the family history for aneurysms and 
consequently did not analyze for it. The general policy at 
the Scripps Clinic is to repair aneurysms greater than 5 cm 
and to follow ancurysms in the 3- to 5-cm range with serial 
computed tomography orultrasonography. Of 15 patients 
with aneurysms greater than 4 cm, nine underwent surgical 
repair. Of six patients with aneurysms greater than 5 cm, 
five underwent surgery, and one declined it. Of nine 
patients with aneurysms measuring 4 to 5 cm, four 
expanded over time and were referred for surgery. 
With regard to the question of cost-efficiency, Our data 
are in general agreement with the analysis presented by 
Quill et al., 21 by Frame, 2° by Russell, 22 and by Collin et al. 4 
We have shown that it is possible to screen at relatively low 
cost and that the cost benefit ratio can be varied by focusing 
on specific subgroups. However, most of the expense, as we 
stated, is related to repair of the detected aneurysms, and 
ultimately society will have to decide whether it is willing 
and able to undertake such an investment. 
Dr. Calvin B. Ernst. (Detroit, Mich.). As usual, this 
report from Scripps is a high-quality, meticulous study and 
provides some important information that I believe de- 
serves emphasis. 
First, as had been pointed out, the study that Sumner 
ct al. reported several years ago suggested that cost is 
currently prohibitive to routinely screen the population for 
aortic aneurysms. Consequently, such screening appears to 
be a societal problem. If society believes that AAA are a 
great risk to the overall health of the general population, 
then such screening tests and screening stations, if you will, 
can be established. 
But the important thing about his study is that first, it 
has identified the population most likely to have an AAA; 
namely, the older smoking man. Second, it has identified 
those who are not necessarily at risk for aneurysms. The 
literature suggests that patients who have peripheral 
vascular disease, CAD, hypertension, or diabetes mellitus 
may be prone to ancurysms. The Scripps data do not 
substantiate hese conclusions. 
Now we can focus on a select group for screening. 
Screening during other vascular laboratory evaluations 
appears to be a simple, inexpensive, quick study of a captive 
population that is already coming to the noninvasive 
laboratory. 
Finally, what percent of these ancurysms identified 
with ultrasonography were also found on abdominal 
examination? 
Dr. Jerry Goldstone (San Francisco, Calif.). In the 
patients who werc mcn over age 65 with a history of 
smoking and in whom you could not do a satisfactory 
examination for whatever reason, would you recommend 
that those people be recalled for a subscqeunt follow-up 
ultrasound examination? 
In other words, is the concern high enough to spend 
that money on those few patients? 
Dr. Wolf. If you consider a 15% prevalence rate as 
sufficient to justify a separate ultrasound study, then yes, it 
is worthwhile. Retrospectively, some aneurysms could be 
diagnosed, but before the examination one of these 
aneurysms were identified, otherwise these patients would 
have been excluded from the study. 
Dr. Christopher K. Zarins (Stanford, Calif.). This 
very interesting study supports the concept that aneurysm 
formation is a manifestation of atherosclerosis. These 
patients were selected because they had peripheral occlusive 
disease. That is why they were studied in the vascular 
laboratory. 
The finding of aneurysms is not surprising because 
onc cxpccts to find an increased incidence of aneurysms 
in this atherosclerotic population, along with CAD and 
smoking. 
It is particularly interesting that you found that the 
patients with aneurysms were older, which, of course, goes 
along with other studies indicating that patients undergo- 
ing operation for aneurysmal disease tend to be older than 
those undergoing aortofemoral bypass for occlusive dis- 
ease. I believe that this is due to the evolution of 
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atherosclerotic plaque with time and the &generative effect 
of plaque on the artery wall. 
Although there are those who believe that the patho- 
genesis of aneurysms has nothing to do with atherosclero- 
sis, 1 believe that this study supports the concept that 
atherosclerosis and aneurysms are really manifestations of
one in the same disease process. 
Dr. Richard L. Treirnan (Los Angeles, Calif.). 
Because you use history of smoking as a criteria, could you 
define your criteria for smoking? I have found that if you 
look at histories from many people they say they're not 
smoking, but if you talk to them they have smoked for 
many years but stopped one year, 3 years, or 5 years earlier. 
What was your criteria for smoking because that is a criteria 
for screening? 
Dr. Wolf. We mention it in the manuscript. Because of 
lack of time I did not show it here. It was more than 20 
cigarettes per day, stopped less than 10 years before the 
examination and for more than 10 years of the patient's life. 
Dr. Kaj H. Johnasen (Seattle, Wash.). As Dr. Ernst 
says, this important study will potentially change our 
behavior. 
Steve Nicholls and I and others have observed an 
apparent correlation between aneurysms and the presence 
of chronic obstructive pulmonary disease (COPD), rather 
than smoking. I wonder if there was an association between 
the presence of aneurysm and COPD in these patients or 
whether, in fact, this was evaluated. 
Dr. ~rolf. We did not study COPD, and we did not 
examine this issue. 
Dr. Wesley S. Moore (Los Angeles, Calif.). If  you 
were to put out a call for smoking men over the age of 65, 
according to the criteria that you have described, in&pen- 
dent of any evidence of peripheral vascular disease, and 
carried it out as a screening program, you could then 
determine whether there was a difference in prevalence in 
aneurysms between those two groups. This might answer 
the question. 
The other question that I had is a practical one. You 
have taken patients who were referred to the vascular 
laboratory for a specific series of tests related to their 
peripheral vascular disease and then went ahead and 
performed an ultrasound examination of the aorta. Were 
you able to charge for this, and, in fact, were you able to 
collect for the charge of doing the study? 
Dr. Wolf. No. This was done on a research basis, and 
we did not charge for the study. 
Dr. Goldstone. It seems like you would have to get 
preauthorization from most health maintenance organiza- 
tions these days. 
Dr. Robert  L. Kistner (Honolulu, Hawaii). I enjoyed 
the study very much, and it reinforced some of the 
persuasions we reported last year in a 5-year eview of our 
aneurysm experience in Hawaii, including a prospective 
study. Our conclusions at that time were that we had to 
narrow screening down into specific indications in the 
atherosclerotic group as well as those with a family history. 
Now you have shown us a very practical way to screen a 
certain part of the population. 
I did have some questions about your screening. In 
your studies of hypertension, did you stratify into systolic 
and diastolic groups? We and others had an indication that 
the diastolic hypertension group might be at higher risk. 
Did you prepare the patients by having them fast for 
ultrasound screening, or did you just take them as they 
came any time of the day? In the ultrasound analysis, did 
you compare the accuracy of your ultrasound ata as you 
did it in the vascular laboratory with computed tomogra- 
phy or any other criterion to know how accurate you are? 
Dr. Wolf. The accuracy of ultrasonography, was 
verified in all patients with aneurysms larger than 4 cm. 
Over the course of years we know that ultrasonography 
from this institution is extremely reliable in measuring the 
size of the aorta. We insisted on an overnight fast, and 
anybody who did not fast overnight before the examination 
was excluded from the study. The definition of hyperten- 
sion was either previously diagnosed hypertension or 
medication received for this diagnosis. 
Dr. George Andros (Burbank, Calif.). In our labora- 
tory, which is probably like most community hospital 
clinical vascular laboratories, the least commonly per- 
formed study is for peripheral arterial disease. Carotid 
artery examinations are requested far more often. 
The question I have for you is whether you would 
extend aneurysm surveillance topatients with carotid artery 
disease because they also have arteriosclerosis? 
Dr. Wolf. It would make sense to extend this screening 
also to patients with carotid artery disease, and I would 
expect he prevalence rate to be similar. We know from 
previous reports that it is high in this patient group too. We 
confined ourselves to lower extremity studies simply 
because of the technical ease with which it can be 
performed. It is basically in the same arterial bed, and the 
patient is already prepared for that. 
Dr. Kenneth D. Mclntyre, Jr. (Galveston, Texas). In 
those patients in whom you found aneurysms did you scan 
their iliac, femoral, and popliteal arteries to determine 
whether associated aneurysms were present? 
Dr. Wolf. No, we did not. This study was strictly 
limited to the infrarenal aorta. The technician measured the 
diameter at the level of the juxtarenal orta, the distal aorta, 
or a greater diameter in between. 
Dr. Stephen C. Nicholls (Seattle, Wash.). The point 
that I was going to make has been brought up already. The 
two risk factors that Cronenwett has identified are COPD 
and diastolic hypertension, and although 1 see that you 
didn't interrogate your patients for pulmonary disease, I 
think it's a little misleading for you to say that hypertension 
is not correlated if you didn't specifically look for diastolic 
hypertension. The Cronenwett data are very clear on this. 
Dr. Wolf. That may be correct. However, the Cronen- 
wett data refer to the incidence of rupture or expansion rate 
of aneurysms, and we were examining the prevalence of 
small aneurysms. 
